Abstract

Mucormycosis corresponds to a potentially fatal invasive fungal disease that has an increasing incidence, mainly in immunocompromised onco-hematological patients and stem-cell transplant recipients. Skin involvement being one of its clinical presentations. We report the case of a 21-year-old patient, diagnosed with acute lymphoblastic leukemia, who developed primary cutaneous mucormycosis caused by Rhizopus arrhizus, confirmed by molecular methods and histology, and who evolved favorably after a large surgical resection and antifungal therapy based on to liposomal amphotericin B and isavuconazole.